GlassScriptPhysician profile
Teri Danielle Jackson
NPI 1447905781
$918.19
in general payments reported to CMS, 2019-2025
23 companies · $76.58 in 2025
The $76.58 reported for 2025 was less than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $376 · 2023: $357 · 2024: $108 · 2025: $76.58.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $542.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $542.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $128.08 | 2022-2023 | Mounjaro, Jardiance |
| Pfizer INC. | $102.52 | 2023-2024 | |
| Abbvie INC. | $92.47 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $47.85 | 2022-2023 | Xifaxan |
| Novo Nordisk INC | $45.43 | 2022-2023 | Wegovy |
| Atland Pharmaceuticals, LLC | $42.10 | 2024 | Tolmetin Sodium, Orphenadrine Citrate, Aspirin and Caffeine |
| Bayer Healthcare Pharmaceuticals INC. | $40.91 | 2022-2023 | |
| Otsuka America Pharmaceutical, INC. | $38.13 | 2022-2023 | Rexulti |
| Novartis Pharmaceuticals Corporation | $37.04 | 2022-2023 | |
| Ultragenyx Pharmaceutical INC. | $37.00 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $32.44 | 2022 | |
| Mylan Specialty L.P. | $32.16 | 2022 | |
| Amgen INC. | $28.84 | 2022 | |
| Aroa Biosurgery Incorporated | $28.61 | 2025 | |
| Sumitomo Pharma America, INC. | $28.60 | 2023 | Gemtesa |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $28.60 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $25.50 | 2023 | Trintellix |
| Xeris Pharmaceuticals, INC. | $21.33 | 2022 | |
| Bausch Health US, LLC | $20.00 | 2023 | Aplenzin, Wellbutrin |
| Sanofi-Aventis U.S. LLC | $17.00 | 2023 | |
| Esperion Therapeutics, INC. | $15.09 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.82 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.67 | 2023 | Jardiance |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Teri Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.